Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.

7043Background: Real-world studies have shown that persistence with intravenous (IV) and subcutaneous (SC) hypomethylating agents (HMAs) among patients (pts) with higher-risk myelodysplastic syndro...